Condition: B-Cell Non-Hodgkins Lymphoma · Sponsor: Hoffmann-La Roche
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
This description comes directly from the study's public registry record.
Reference Study ID Number: GO45434 https://forpatients.roche.com/ No email attachments. · 888-662-6728 · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Alaska Oncology & Hematology, LLC | Anchorage, Alaska, United States | Recruiting |
| Community Cancer Institute (CCI) | Clovis, California, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| Los Angeles Cancer Network | Glendale, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials | Panorama City, California, United States | Recruiting |
| Zuckerberg San Francisco General Hospital | San Francisco, California, United States | Recruiting |
| The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente | Torrance, California, United States | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Aurora, Colorado, United States | Recruiting |
| North Florida/ South Georgia VA Medical Center | Gainesville, Florida, United States | Recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06806033